Healthcare providers home page

For Most Mild to Moderate Crohn's Patients

References

  1. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940-987.
  2. ENTOCORT EC [package insert]. Wilmington, DE: AstraZeneca; 2005.
  3. Allan RN. Crohn’s disease of the small intestine—ileum and right colon. In: Allan RN, Rhodes JM, Hanauer SB, eds. Inflammatory Bowel Diseases. New York, NY: Churchill Livingstone; 1997:589-595.
  4. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331(13):842-845.
  5. Schoon EJ, Bollani S, Mills PR, et al; The MATRIX Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol. 2005;3(2):113-121.
  6. Campieri M, Ferguson A, Doe W, Persson T, Nilsson L-G; The Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Gut. 1997;41(2):209-214.
  7. Thomsen OØ, Cortot A, Jewell D, et al; The International Budesonide-Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn’s disease. N Engl J Med. 1998;339(6):370-374.
  8. Data on file, DA-ENT-10, AstraZeneca.
  9. Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100(8):1780-1787.
  10. Cortot A, Colombel J-F, Rutgeerts P, et al; The International Budesonide Study Group. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut. 2001;48(2):186-190.
 

*For Crohn’s disease involving the ileum and/or ascending colon, ENTOCORT EC is indicated for the treatment of mild to moderate active disease (up to 8 weeks with repeated 8-week courses as necessary) and the maintenance of clinical remission of mild to moderate disease for up to an additional 3 months.

Clinical remission is defined as a Crohn’s Disease Activity Index (CDAI) score of ≤150.

Important safety information

Since ENTOCORT EC® is a glucocorticosteroid (GCS), general warnings about GCSs should be followed. GCSs can reduce the response of the hypothalamus-pituitary-adrenal axis to stress. Supplementation with a systemic GCS is recommended before surgery or other stress situations. Adrenocortical function monitoring may be required in patients being transferred to ENTOCORT EC from a systemic GCS, and the dose of the systemic GCS should be reduced cautiously.

Patients on drugs that suppress the immune system are more susceptible to infections and should avoid exposure to infections such as chicken pox or measles.

Patients with moderate to severe liver disease and patients who are concomitantly taking ketoconazole or any other CYP3A4 inhibitor should be closely monitored for increased signs and/or symptoms of hypercorticism.

The adverse event profile of ENTOCORT EC in 6 mg once daily clinical trial treatment (52-week) was similar to that of 9 mg once daily clinical trial treatment (8-week). The most frequently reported adverse events in clinical trials of ENTOCORT EC were headache, respiratory infection, nausea, and symptoms of hypercorticism.

Please see full prescribing information.